Development of the Rheumatoid Arthritis Symptom Questionnaire (RASQ): a patient reported outcome scale for measuring symptoms of rheumatoid arthritis
Development of the Rheumatoid Arthritis Symptom Questionnaire (RASQ): a patient reported outcome scale for measuring symptoms of rheumatoid arthritis
复制标题
DOI：
10.1080/03007995.2017.1338562
复制
发表时间：
2017-01-01
影响因子：
2.3
通讯作者：
Ganguli, Arijit
中科院分区：
文献类型：
--
作者：
Banderas, Benjamin;Skup, Martha;Ganguli, Arijit
背景资料：类风湿性关节炎（RA）是一种慢性、进行性炎症性自身免疫性疾病，可显著降低健康相关生活质量（HRQoL），并导致严重残疾和早期死亡。患者报告结局（PRO）工具用于评估患者对RA症状和影响的体验，并可捕获RA治疗效果。为了解决现有PRO工具的局限性，本研究的目的是建立一个新的工具，风湿性关节炎症状问卷（RASQ）的内容效度，以评估RA的体征和症状。方法：RA患者最重要的和相关的体征和症状的概念，通过有针对性的审查发表的文献，专家意见，和概念启发患者访谈。与患者进行认知访谈，以测试的可理解性和全面性的RASQ.Results：七个症状出现一致的概念研究：关节疼痛，关节肿胀，关节僵硬，关节压痛，关节温暖，肌肉疼痛，疲劳。除了单个影响项目外，还开发了项目内容草案以评估这些症状，从而产生了三个RASQ版本：两个版本使用7天回忆期（一个评估最严重症状，另一个评估平均症状），第三个版本使用24小时回忆期评估最严重症状。认知访谈结果表明患者的理解和能力，使用instrument.Conclusions：内容效度的RASQ建立在仪器开发指南。RASQ通过评估对患者最重要的RA体征和症状填补了测量空白。评估RASQ的心理测量特性的研究正在进行中。
Background: Rheumatoid arthritis (RA), a chronic, progressive inflammatory, autoimmune disease, can substantially reduce health-related quality of life (HRQoL) and lead to severe disability and early mortality. Patient-reported outcome (PRO) instruments are used to assess the patient experience of RA symptoms and impacts, and can capture RA treatment effects. To address limitations in existing PRO instruments, this research aimed to establish the content validity of a new instrument, the Rheumatoid Arthritis Symptom Questionnaire (RASQ), to assess the signs and symptoms of RA.Method: The most important and relevant sign and symptom concepts for RA patients were identified through a targeted review of the published literature, expert opinion, and concept elicitation patient interviews. Cognitive interviews were conducted with patients to test the comprehensibility and comprehensiveness of the RASQ.Results: Seven symptoms emerged consistently across the conceptual research: joint pain, joint swelling, joint stiffness, joint tenderness, joint warmth, muscle pain, and tiredness. Draft item content was developed to assess these symptoms, in addition to a single impact item, resulting in three RASQ versions: two utilizing a 7day recall period (one assessing symptoms at their worst, the other on average) and a third using a 24hour recall period assessing symptoms at their worst. Cognitive interview results demonstrated patient understanding and ability to use the instrument.Conclusions: Content validity of the RASQ was established in accordance with instrument development guidelines. The RASQ fills a measurement gap by assessing the RA signs and symptoms most important to patients. Research evaluating the RASQ's psychometric properties is underway.